Published in

Elsevier, Polyhedron, (68), p. 312-318

DOI: 10.1016/j.poly.2013.11.001

Links

Tools

Export citation

Search in Google Scholar

Ruthenium(II)/4,6-dimethyl-2-mercaptopyrimidine complexes: Synthesis, characterization, X-ray structures and in vitro cytotoxicity activities on cancer cell lines

Journal article published in 2014 by Melina A. Mondelli, Angelica E. Graminha ORCID, Rodrigo S. Corrêa, Monize M. da Silva, Andréa P. Carnizello, Gustavo Von Poelhsitz ORCID, Javier Ellena, Victor M. Deflon, Giovanni F. Caramori, Maria H. Torre, Denise C. Tavares, Alzir A. Batista
This paper is available in a repository.
This paper is available in a repository.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Red circle
Postprint: archiving forbidden
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

The complexes [RuCl(SpymMe(2)-N,S)(2)(NO)] (1) and [Ru(dppb)(SpymMe(2)-N,S)(2)] (2) (dppb = 1,4-bis(diphenylphosphino)butane, SpymMe(2) = deprotonated 4,6-dimethyl-2-mercaptopyrimidine) were obtained and characterized by elemental analysis, spectroscopic techniques including X-ray crystallography, conductimetry and cyclic voltammetry. Energy Decomposition Analysis (EDA) calculation indicated strong intermolecular interaction between monomers of complex I, as suggested by the H-1 NMR spectrum of this complex, in chloroform solution. Additionally, preliminary tests were carried out, in order to evaluate the cytotoxicity activity on cancer cell lines of the new complexes, and the free ligands, against MDA-MB-231 (breast cancer), Hela (cervical cancer), U251 (glioma cancer) tumor cell lines and the V79 (Chinese lung fibroblast hamster) cell line. The best result was obtained for the complex 1 with IC50 value of 0.11 +/- 0.02, against MDA-MB-231 tumor cells.